Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 48

1.

A phase II study of troglitazone, an activator of the PPARgamma receptor, in patients with chemotherapy-resistant metastatic colorectal cancer.

Kulke MH, Demetri GD, Sharpless NE, Ryan DP, Shivdasani R, Clark JS, Spiegelman BM, Kim H, Mayer RJ, Fuchs CS.

Cancer J. 2002 Sep-Oct;8(5):395-9.

PMID:
12416897
2.

Use of the peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer: a phase II study.

Burstein HJ, Demetri GD, Mueller E, Sarraf P, Spiegelman BM, Winer EP.

Breast Cancer Res Treat. 2003 Jun;79(3):391-7.

PMID:
12846423
3.

Troglitazone improves psoriasis and normalizes models of proliferative skin disease: ligands for peroxisome proliferator-activated receptor-gamma inhibit keratinocyte proliferation.

Ellis CN, Varani J, Fisher GJ, Zeigler ME, Pershadsingh HA, Benson SC, Chi Y, Kurtz TW.

Arch Dermatol. 2000 May;136(5):609-16.

PMID:
10815854
4.

Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo.

Yu J, Qiao L, Zimmermann L, Ebert MP, Zhang H, Lin W, Röcken C, Malfertheiner P, Farrell GC.

Hepatology. 2006 Jan;43(1):134-43.

PMID:
16374840
5.

Peroxisome proliferator-activated receptor gamma (PPargamma) as a novel target for prostate cancer.

Smith MR, Kantoff PW.

Invest New Drugs. 2002 May;20(2):195-200. Review.

PMID:
12099579
6.

Decreased synthesis of matrix metalloproteinase-7 and adhesion to the extracellular matrix proteins of human colon cancer cells treated with troglitazone.

Sunami E, Tsuno NH, Kitayama J, Saito S, Osada T, Yamaguchi H, Tomozawa S, Tsuruo T, Shibata Y, Nagawa H.

Surg Today. 2002;32(4):343-50.

PMID:
12027200
7.

Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer.

Mueller E, Smith M, Sarraf P, Kroll T, Aiyer A, Kaufman DS, Oh W, Demetri G, Figg WD, Zhou XP, Eng C, Spiegelman BM, Kantoff PW.

Proc Natl Acad Sci U S A. 2000 Sep 26;97(20):10990-5.

8.

Peroxisome proliferator-activated receptor gamma agonist ligands stimulate a Th2 cytokine response and prevent acute colitis.

Saubermann LJ, Nakajima A, Wada K, Zhao S, Terauchi Y, Kadowaki T, Aburatani H, Matsuhashi N, Nagai R, Blumberg RS.

Inflamm Bowel Dis. 2002 Sep;8(5):330-9.

PMID:
12479648
9.

Raltitrexed plus oxaliplatin in the treatment of metastatic colorectal cancer.

Cortinovis D, Bajetta E, Di Bartolomeo M, Dognini G, Beretta E, Ferrario E, Ricotta R, Buzzoni R.

Tumori. 2004 Mar-Apr;90(2):186-91.

PMID:
15237580
10.

A retrospective study of bifractionated CPT-11 with LF5FU infusion (FOLFIRI-3) in colorectal cancer patients pretreated with oxaliplatin and CPT-11 containing chemotherapies.

Viel E, Demarchi MF, Chaigneau L, Nguyen T, Legat C, Stein U, Thiery-Vuillemin A, Limat S, Pivot X, Borg C.

Am J Clin Oncol. 2008 Feb;31(1):89-94. doi: 10.1097/COC.0b013e318134ee9c.

PMID:
18376234
11.

Rescue chemotherapy using multidrug chronomodulated hepatic arterial infusion for patients with heavily pretreated metastatic colorectal cancer.

Bouchahda M, Adam R, Giacchetti S, Castaing D, Brezault-Bonnet C, Hauteville D, Innominato PF, Focan C, Machover D, Lévi F.

Cancer. 2009 Nov 1;115(21):4990-9. doi: 10.1002/cncr.24549.

12.

The PPAR(gamma) K422Q mutation does not contribute to troglitazone inefficiency in colon cancer treatment.

Bouancheau D, Buecher B, Jarry A, Simon B, Masson D, Cassagnau E, Hamelin R, Laboisse CL, Bézieau S, Denis MG.

Cancer Lett. 2005 Jun 16;224(1):111-6.

PMID:
15911106
13.

The effects of troglitazone, an insulin-sensitizing agent, on the endothelial function in early and late type 2 diabetes: a placebo-controlled randomized clinical trial.

Caballero AE, Saouaf R, Lim SC, Hamdy O, Abou-Elenin K, O'Connor C, Logerfo FW, Horton ES, Veves A.

Metabolism. 2003 Feb;52(2):173-80.

PMID:
12601628
14.

Pretreatment with troglitazone decreases lethality during endotoxemia in mice.

Reynolds K, Novosad B, Hoffhines A, Gipson J, Johnson J, Peters J, Gonzalez F, Gimble J, Hill M.

J Endotoxin Res. 2002;8(4):307-14.

PMID:
12230920
15.

Phase II study of rubitecan, an oral camptothecin in patients with advanced colorectal cancer who have failed previous 5-fluorouracil based chemotherapy.

Patel H, Stoller R, Auber M, Potter D, Cai C, Zamboni W, Kiefer G, Matin K, Schmotzer A, Ramanathan RK.

Invest New Drugs. 2006 Jul;24(4):359-63.

PMID:
16525767
17.

Colorectal cancer metastases: surgical indications and multimodal approach.

Ciferri E, Bondanza GS, Municinò O, Castagnola M, Gazzaniga GM.

Hepatogastroenterology. 2003 Nov-Dec;50(54):1836-46.

PMID:
14696416
18.

Intensive systemic chemotherapy combined with surgery for metastatic colorectal cancer: results of a phase II study.

Taïeb J, Artru P, Paye F, Louvet C, Perez N, André T, Gayet B, Hebbar M, Goebel FM, Tournigand C, Parc R, de Gramont A.

J Clin Oncol. 2005 Jan 20;23(3):502-9.

PMID:
15659495
19.

Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer.

Eisen T, Thatcher N, Leyvraz S, Miller WH Jr, Couture F, Lorigan P, Lüthi F, Small D, Tanovic A, O'Brien M.

Lung Cancer. 2009 Apr;64(1):60-5. doi: 10.1016/j.lungcan.2008.06.017. Epub 2008 Aug 9.

PMID:
18692272
20.

Peroxisome proliferator-activated receptor gamma ligands suppress colon carcinogenesis induced by azoxymethane in mice.

Osawa E, Nakajima A, Wada K, Ishimine S, Fujisawa N, Kawamori T, Matsuhashi N, Kadowaki T, Ochiai M, Sekihara H, Nakagama H.

Gastroenterology. 2003 Feb;124(2):361-7.

PMID:
12557142

Supplemental Content

Support Center